Business
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 (S1P5 Receptor Agonist) in Multiple System Atrophy at the 7th World Parkinson Congress (WPC)
OSAKA, Japan, May 27, 2026--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") announced the presentation of data from the randomized, double-blind, placebo-controlled, Phase 2 study of ONO-2808（ONO-2808-03 study）for the treatment of multiple system atrophy (MSA) at the 7th World Parkinson Congress, held from May 24 to May 27, 2026, in Phoenix, Arizona, USA.
About this update from Ono Pharmaceutical Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":252,"url":"https://media.zenfs.com/en/business-wire.com/e822d235b0e0e5e14fb3ea83e26b8abf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2YtSmZF7ZBAlxMCoZ3p2tQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNA--/https://media.zenfs.com/en/business-wire.com/e822d235b0e0e5e14fb3ea83e26b8abf","width":480,"height":252},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/jqZ.4SGpz1k0FLzdjLZJoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMzNg--/https://media.zenfs.com/en/business-wire.com/e822d235b0e0e5e14fb3ea83e26b8abf","width":480,"height":252}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"In the Phase 2 study, the incidence of treatment-emergent adverse events was similar to placebo, and no unexpected safety signals were identified","length":145,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"In mUMSARS scores and MRI-based brain volume assessment (vMRI), a tendency toward suppressed disease progression was observed compared to the placebo group","length":155,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Based on the results of the Phase 2 study, a pivotal Phase 3 study will be initiated","length":84,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":384,"olType":false},{"type":"text","content":"OSAKA, Japan, May 27, 2026--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") announced the presentation of data from the randomized, double-blind, placebo-controlled, Phase 2 study of ONO-2808（ONO-2808-03 study）for the treatment of multiple system atrophy (MSA) at the 7th World Parkinson Congress, held from May 24 to May 27, 2026, in Phoenix, Arizona, USA.","length":435,"tagName":"p"},{"type":"text","content":"This presentation includes results of the double-blind core part of the ONO-2808-03 study at 24 weeks. In addition to the incidence of treatment-emergent adverse events (TEAEs), which is the primary endpoint, efficacy is evaluated using multiple exploratory indicators, including the modified Unified Multiple System Atrophy Rating Scale* (mUMSARS). TEAEs incidence was similar to placebo (91%, n=21/23) and ONO-2808 (93%, n=64/69), with no unexpe...